Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients
试验速览
- 阶段
- 不适用
- 入组人数
- 210
- 试验地点
- 8
- 主要终点
- Patient-defined "treatment success"
研究概览
简要总结
Our long-term goal is to integrate non-small cell lung cancer patient treatment preferences into clinical treatment planning.
详细描述
The following specific aims are proposed:
Aim 1: Determine whether individual patients' preferences, characteristics, and treatment experiences affect the definition of treatment success.
Aim 2: Determine how to best predict real-life patients' treatment choices based on patients' preferences of adverse events.
Aim 3: Determine whether physicians are likely to change their oncologic clinical practice after receiving a detailed communication of their patients' preferences of adverse events.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide consent
- •Greater than or equal to 19 years of age
- •Diagnosed with stage IV non-small cell lung cancer (NSCLC)
- •Able to understand spoken English
- •Eligible to undergo chemotherapy for stage IV NSCLC, to include, but not limited to, those who:
- •have not yet started chemo
- •are currently undergoing chemo for stage IV NSCLC
- •have completed first line stage IV NSCLC chemo or progressed to maintenance for stage IV NSCLC within the last 30 days
- •elect to have chemo elsewhere -- not at one of the study sites
- •decline chemo
排除标准
- •Age <19 years
- •Not willing and/or able to provide consent
- •Not able to understand spoken English
- •Not eligible to undergo chemotherapy for stage IV NSCLC
结局指标
主要结局
Patient-defined "treatment success"
时间窗: Baseline
In advanced stage NSCLC patients does patient-defined "treatment success" differ when both survival and patient preferences of adverse events are accounted for, compared to when success is measured solely by survival? And does it also differ based on individual patient characteristics?
Patients' will to experience adverse events
时间窗: Baseline
Will the serious adverse events that an advanced stage NSCLC patient is willing to experience as part of his/her treatment differ after a real-life treatment experience, compared to before treatment?
次要结局
- Summary score derived from patient preferences of adverse events(Up to three months)
研究者
KM Islam, PhD
Principal Investigator
University of Nebraska